EichorEICHOR
Condition: Her2 Positive Solid Tumors Synced from ClinicalTrials.gov · August 06, 2026

Recruiting studies: Her2 Positive Solid Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
Phase 1/Phase 2 · 19 location(s) · Yuhan Corporation · NCT05523947At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860TGW211 for Click-Cleavable Imaging in HER2-Positive Cancers.
EARLY_Phase 1 · 1 location(s) · Radboud University Medical Center · NCT07009184HER-2 B Cell Peptide Vaccine
Phase 1 · 1 location(s) · Pravin T.P Kaumaya · NCT06414733Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366IKS014 in Advanced Solid Tumors That Express HER2
Phase 1 · 13 location(s) · Iksuda Therapeutics Ltd. · NCT05872295Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Ensem Therapeutics · NCT06993844The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/Phase 2 · 77 location(s) · PMV Pharmaceuticals, Inc · NCT04585750Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07589517Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07486089A Study of VRN101099 in Patients With HER2-Positive Solid Tumors
Phase 1 · 1 location(s) · Voronoi, Inc · NCT06806982HF50 in HER-2 Positive and Low-expression Advanced Solid Tumors
EARLY_Phase 1 · 1 location(s) · HighField Biopharmaceuticals Corporation · NCT06822998A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07612891ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast C
Phase 2 · 44 location(s) · ALX Oncology Inc. · NCT07007559Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Phase 1 · 1 location(s) · Baylor College of Medicine · NCT03740256Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Phase 1/Phase 2 · 17 location(s) · Aminex Therapeutics, Inc. · NCT07287917A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 · 18 location(s) · NiKang Therapeutics, Inc. · NCT07029399PRE-I-SPY Phase I/Ib Oncology Platform Program
Phase 1 · 7 location(s) · QuantumLeap Healthcare Collaborative · NCT05868226Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for H
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT07137416A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumo
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05673928EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07617805A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors
Phase 1/Phase 2 · 3 location(s) · AP Biosciences Inc. · NCT06669975A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Phase 1 · 18 location(s) · Totus Medicines · NCT05683418HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06824155A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 · 53 location(s) · Iambic Therapeutics, Inc · NCT06253871Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors
NA · 1 location(s) · UTC Therapeutics Inc. · NCT06658951Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Ot
Phase 1/Phase 2 · 33 location(s) · Novartis Pharmaceuticals · NCT06726148Gene Therapy for HER-Positive Cancer (SENTRY-HER2)
Phase 1/Phase 2 · 11 location(s) · Vironexis Biotherapeutics Inc. · NCT07192432A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid
Phase 1 · 2 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06503783A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
Phase 1 · 6 location(s) · Edgewood Oncology Inc. · NCT04872166
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.